10-Q: CareDx Q2 2025: Mixed Results Amid Legal Settlements

CareDx reports a 6% revenue decline to $86.7 million in Q2 2025, driven by prior period adjustments, but sees growth in product and digital solutions, alongside significant legal developments.

Summary

• Total revenue for the three months ended June 30, 2025, was $86.7 million, a 6% decrease from $92.3 million in the same period of 2024.
• Testing services revenue decreased by 13% to $62.0 million in Q2 2025, primarily due to negative revenue adjustments of $3.8 million related to tests performed in prior periods.
• Excluding these adjustments, testing services revenue increased by 14% due to a 13% year-over-year growth in testing volume to 49,500 tests.
• Product revenue increased by 12% to $11.8 million, driven by higher sales of commercial NGS-based kitted solutions.
• Patient and digital solutions revenue grew by 19% to $12.8 million, mainly from Ottr software and increased pharmacy sales.
• Net loss for Q2 2025 was $8.6 million, compared to a net loss of $4.6 million in Q2 2024.
• For the six months ended June 30, 2025, total revenue was $171.4 million, a 4% increase from $164.3 million in the same period of 2024.
• Net loss for the six months ended June 30, 2025, improved to $18.9 million from $24.5 million in the prior year period.
• Cash, cash equivalents, and marketable securities stood at $186 million as of June 30, 2025, down from $260.6 million at December 31, 2024, after a $50 million share repurchase.
• A material weakness in internal control over financial reporting, identified as of December 31, 2022, remains unremediated as of June 30, 2025.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to a decline in overall revenue, increased quarterly net loss, significant cash burn from operations, and the persistence of a material weakness in internal controls. While there are positive developments in product and digital solutions revenue growth and favorable outcomes in some legal disputes, the financial performance and ongoing litigation risks, particularly the potential for a large judgment if Natera's appeal succeeds, weigh heavily on the outlook. The uncertainty around future Medicare reimbursement rates also adds to the negative sentiment.

Positives

• Product revenue increased by 12% in Q2 2025 and 18% for the six months ended June 30, 2025, driven by higher sales of commercial NGS-based kitted solutions.
• Patient and digital solutions revenue increased by 19% in Q2 2025 and 22% for the six months ended June 30, 2025, primarily due to growth in Ottr software and pharmacy sales.
• Testing services volume increased by 13% year-over-year in Q2 2025, indicating growing adoption of their core services.
• Net loss improved by 23% for the six months ended June 30, 2025, compared to the same period in 2024.
• The SEC concluded its investigation into the company with no enforcement action recommended.
• The Department of Justice (DOJ) closed its False Claims Act investigation into the company with no finding of wrongdoing.
• A jury found Natera violated the Lanham Act by falsely advertising its Prospera transplant test, and the court upheld this finding, issuing an injunction against Natera.
• The court overturned a prior jury verdict that found CareDx infringed Natera's patents, concluding Natera's patents 11,111,544 and 10,655,180 were invalid for lack of written description.

Negatives

• Total revenue decreased by 6% in Q2 2025, primarily due to negative revenue adjustments of $3.8 million related to prior period tests.
• Testing services revenue decreased by 13% in Q2 2025, despite an increase in testing volume, due to prior period revenue adjustments.
• Net cash used in operating activities was $16.7 million for the six months ended June 30, 2025, compared to cash provided of $3.6 million in the prior year, indicating a worsening cash flow from operations.
• Cash, cash equivalents, and marketable securities decreased significantly from $260.6 million at December 31, 2024, to $186.3 million at June 30, 2025, partly due to share repurchases.
• The company recorded a litigation settlement expense of $5.7 million for the six months ended June 30, 2025, related to a securities class action lawsuit.
• A material weakness in internal control over financial reporting, identified as of December 31, 2022, remains unremediated as of June 30, 2025, posing risks to financial reporting accuracy.
• The company faces ongoing appeals from Natera regarding patent invalidation, with a potential loss of up to $96.3 million plus interest if Natera prevails.
• A new draft proposed revision to the Medicare LCD (DL40058, DL40060) for AlloSure tests was released, which could introduce new coverage criteria, utilization limitations, and bundled payments, potentially leading to lower reimbursement rates.
• The recommended Medicare reimbursement rate for PLA Code 0540U (AlloSure tests) is $2,753, which represents an $88 decrease for AlloSure Kidney from its current pricing.

Risks

• Continued net losses are expected for the next several years due to significant operating expenses for R&D, commercialization, and acquisitions.
• Substantial portion of revenue is from Medicare, and loss or significant reduction in reimbursement from Medicare would severely affect financial performance.
• Uncertainty regarding final pricing under the new CPT code (PLA Code 0540U) for AlloSure tests, with potential for lower reimbursement rates.
• The new draft proposed revision to the Medicare LCD (DL40058, DL40060) could introduce new coverage criteria, utilization limitations, and bundled payments, adversely affecting business.
• Financial results are largely dependent on sales of AlloSure Kidney, AlloMap Heart, AlloSure Heart, HeartCare, and AlloSure Lung tests and products; failure to increase sales or commercialize new solutions would impair revenue and profitability.
• Health insurers and other third-party payers may revoke coverage, not cover future solutions, or provide inadequate reimbursement, jeopardizing commercial prospects.
• Ongoing litigation, including appeals from Natera regarding patent infringement, could result in costly litigation, settlements/judgments, and diversion of management attention and resources.
• Development and commercialization of additional diagnostic solutions is a lengthy, complex, and risky process, with no guarantee of success or timely market entry.
• Failure to keep pace with rapid technological change in diagnostic testing in transplantation could render existing solutions obsolete.
• Clinicians, hospital administrators, medical centers, and laboratories may not adopt diagnostic solutions due to historical practices or more favorable reimbursement for alternative monitoring methods (e.g., biopsies).
• Inability to successfully compete with established players and new entrants in the clinical surveillance of transplantation field could prevent revenue increase or profitability.
• Failure to continually update products on a timely basis could impair ability to attract and retain customers and harm competitive position.
• Research and development efforts may be hindered by inability to acquire or contract for access to tissue and blood samples.
• Inability to maintain existing clinical collaborations and enter into new ones could delay product commercialization and development.
• Inability to successfully manage growth and support demand for tests could harm business, reputation, and ability to provide timely services.
• Reliance on sole source suppliers for laboratory instruments and key reagents exposes the company to supply chain risks and potential interruptions.
• International expansion exposes the company to business, regulatory, political, operational, financial, and economic risks associated with doing business outside the United States.
• Incorporation of AI technologies into internal processes may present business, compliance, and reputational risks, including enhanced governmental scrutiny and potential liabilities.
• Disputes with labor unions (e.g., IF Metall in Sweden) could adversely affect operations and financial results.
• Unfavorable economic and market conditions, including inflation, could adversely affect operating results.
• Fluctuations in effective tax rate and potential obligations in tax jurisdictions in excess of accruals.
• Risk of liability for damages from hazardous materials use.
• Changes in accounting rules and regulations could result in unfavorable accounting changes or require changes to compensation policies.
• Current or future restructuring plans may not optimize costs, simplify structure, or may materially impair business operations.
• Intangibles, including goodwill, acquired in connection with acquisitions may subsequently be impaired, increasing net accumulated deficit.
• Recent and future acquisitions and investments could disrupt business, harm financial condition, dilute ownership, and increase debt or expense.
• Billing complexities associated with obtaining payment or reimbursement for solutions may negatively affect revenue, cash flows, and profitability, including audits and potential recoupments.
• Healthcare reform measures could hinder or prevent commercial success of diagnostic solutions.
• Non-compliance with CLIA, FDA, and other federal and state laws and regulations governing clinical laboratories and LDTs could lead to sanctions or harm business.
• Security breaches, loss of data, and other disruptions could compromise sensitive information, expose to liability, and harm reputation.
• Volatility in stock price due to fluctuating operating results, market conditions, and other factors.
• Sales of substantial amounts of common stock by insiders or under Rule 10b5-1 plans could adversely affect stock price.
• No dividends expected in the foreseeable future; reliance on stock appreciation for return.
• Stock repurchases might limit ability to pursue other growth opportunities.
• Inability to substantially utilize net operating loss carryforwards could harm financial results due to Section 382 limitations.
• Organizational documents and Delaware law make a takeover more difficult, potentially limiting stock price.
• Designation of federal district courts as exclusive forum for Securities Act claims could limit stockholders' ability to obtain favorable judicial forum.
• Costs and demands from complying with public company laws and regulations.
• Lack of equity research analyst coverage or unfavorable commentary could cause stock price decline.
• Techniques employed by short sellers may drive down the market price of common stock.

Future Outlook

The company expects to continue incurring significant operating expenses for research and development, commercialization, and acquisitions, anticipating net losses for the next several years. Future revenue growth depends on continued usage and acceptance of current and future solutions, demand for services and products, and maintaining and securing reimbursement. The company is evaluating the potential impact of new accounting standards on financial statement disclosures. There is uncertainty regarding the final Medicare reimbursement rate for PLA Code 0540U, expected January 1, 2026, and the outcome of a new draft LCD for AlloSure tests, which could introduce new coverage criteria and payment concepts. The company intends to vigorously defend against ongoing litigation and appeals, including from Natera, and is committed to remediating the identified material weakness in internal control over financial reporting.

Management Comments

• Management is committed to maintaining a strong internal control environment and is continuing to take actions to remediate the material weakness in internal control over financial reporting.
• The company believes its existing cash balance and expected cash from existing operations, including cash from current and future license and collaboration agreements, will be sufficient to meet anticipated cash requirements for the next 12 months.
• The company intends to defend vigorously against ongoing litigation and believes it has good and substantial defenses to the claims alleged in the suits, but there is no guarantee of prevailing.

Industry Context

The diagnostic testing in transplantation field is evolving rapidly, characterized by technological development and innovation. CareDx operates in a competitive environment with established players and new entrants developing molecular diagnostic tests for post-transplant surveillance. The industry faces challenges related to payer coverage, reimbursement policies, and the adoption of new technologies over traditional methods like biopsies. Regulatory scrutiny, particularly from the FDA regarding laboratory-developed tests (LDTs) and from CMS regarding reimbursement, continues to shape the landscape. The increasing focus on ESG factors and the integration of AI technologies are also emerging trends impacting the sector.

Comparison to Industry Standards

• CareDx's AlloSure Kidney competes with existing diagnostic tests utilizing biopsy samples and general clinical chemistry tests. Competitors in molecular diagnostics for post-transplant surveillance include Natera, Eurofins, Oncocyte, and Verici.
• For heart transplant recipients, AlloSure Heart, AlloMap Heart, and HeartCare compete with biopsies and echocardiography, supplemented by general clinical chemistry tests. Natera and Eurofins also offer molecular diagnostics in this area.
• AlloSure Lung competes with spirometry and biopsy for lung function assessment and rejection diagnosis, with Natera also offering molecular diagnostics.
• In pre-transplant typing, QTYPE competes with other quantitative PCR products from companies like Thermo Fisher, as well as next-generation sequencing (NGS) typing products.
• For patient and digital solutions, CareDx competes with various application software developers in healthcare, including Phoenix (Epic's transplant application) for EMR solutions, and hospital-affiliated/specialty pharmacies for patient solutions.

Management Changes

Corporate Governance

Legal Proceedings

• **Natera False Advertising Suit (CareDx vs. Natera):** Jury found Natera violated the Lanham Act by falsely advertising its Prospera transplant test. The court upheld the jury verdict but not the monetary damages ($44.9 million) and issued an injunction against Natera. The case was remanded by the Third Circuit for additional findings, and the court later found sufficient evidence to support the jury's findings of falsity on eight advertisements by Natera. CareDx has not recorded a receivable or gain from the judgment.
• **Natera Patent Infringement Suits (Natera vs. CareDx):** Natera alleged AlloSure infringed its patents. A jury found CareDx infringed U.S. Patent 11,111,544, awarding Natera $96.3 million in damages. However, the court subsequently overturned this verdict, concluding that Natera's U.S. Patents 11,111,544 and 10,655,180 were invalid for lack of written description. Natera has appealed this invalidation. Natera's U.S. Patent 10,597,724 was dismissed by the court, and Natera's appeal was initially dismissed but a second appeal was filed and denied dismissal. The PTO issued a reexamination certificate finding Natera had overcome prior rejections for U.S. Patent 11,111,544. CareDx derecognized the $96.3 million liability, but a potential loss of up to this amount plus interest exists if Natera prevails on appeal.
• **United States Department of Justice (DOJ) and Securities and Exchange Commission (SEC) Investigations:** The SEC concluded its investigation into the company with no enforcement action recommended. The DOJ closed its False Claims Act investigation, declining to intervene in a qui tam action filed by a former employee, with no finding of wrongdoing. The private plaintiff in the qui tam action has filed an amended complaint, which CareDx intends to vigorously defend against.
• **Securities Class Action:** An agreement-in-principle was reached to settle the federal securities class action for approximately $20.25 million. The District Court preliminarily approved the settlement, triggering the company's obligation to fund its portion. The company recorded $20.25 million as accrued litigation settlement expense and $14.9 million in expected insurance proceeds.
• **Derivative Actions:** Two stockholder derivative actions (Edelman v. Bickerstaff and Burns Derivative Action) are ongoing, alleging breaches of fiduciary duty and other claims. The Edelman Derivative Action has reached an agreement in principle to resolve the case, subject to attorney fee negotiation. The Burns Derivative Action remains stayed with ongoing settlement discussions.
• **Insurance Matter:** The company filed a lawsuit against its directors and officers liability insurance carriers seeking a declaration that costs and fees incurred in responding to governmental investigatory requests are covered. The Superior Court granted summary judgment to the insurers, and the company is appealing. The policies provide up to $15 million in coverage limits. Resolution of the Securities Class Action may moot this matter.

Stakeholder Impact

• **Shareholders:** Experience dilution from equity compensation, potential impact from stock repurchase programs, and significant volatility due to ongoing litigation and financial performance. The material weakness in internal controls could erode confidence.
• **Employees:** Impacted by management changes (new CFO), stock-based compensation plans, and potential future restructuring efforts. Labor union relations in Sweden could affect employees there.
• **Customers (Transplant Centers, Labs, Patients):** Continued access to diagnostic services and products, but potential changes in Medicare reimbursement policies could affect access or cost. Ongoing litigation may raise concerns about product reliability or company stability.
• **Suppliers:** Continued reliance on sole-source suppliers for key reagents and instruments, making them critical partners.
• **Creditors:** No debt outstanding as of June 30, 2025, but significant cash burn and ongoing losses could impact future creditworthiness if additional capital is needed.

Next Steps

• Continue to develop and commercialize potential new testing services, products, and patient and digital solutions.
• Conduct additional clinical studies to generate data on existing and planned future testing services.
• Monitor and respond to the Medicare repricing process for PLA Code 0540U, with final rates expected January 1, 2026.
• Engage in the comment period for the new draft proposed revision to the Medicare LCD (DL40058, DL40060) for AlloSure tests.
• Vigorously defend against Natera's appeals regarding patent invalidation.
• Continue to defend against the amended qui tam action filed by the private plaintiff.
• Negotiate attorney fees for the agreement in principle to resolve the Edelman Derivative Action.
• Continue settlement discussions in the Burns Derivative Action.
• Pursue appeal of the D&O liability insurance matter.
• Continue to implement and monitor remediation plans for the material weakness in internal control over financial reporting.
• Evaluate the potential effect of new accounting standards (ASU 2023-09 and ASU 2024-03) on financial statement disclosures.

Key Dates

Recommendation

CareDx presents a mixed financial picture. While product and digital solutions revenue show strong growth and testing volume is increasing, overall revenue declined in Q2 2025 due to prior period adjustments. The company continues to incur significant net losses and experienced a substantial cash burn from operations. The ongoing material weakness in internal controls is a notable concern for financial reporting reliability. On the legal front, favorable outcomes in the SEC/DOJ investigations and the overturning of a large patent infringement verdict are positives, but Natera's appeals and other derivative actions introduce significant uncertainty and potential future liabilities. The potential for reduced Medicare reimbursement rates also poses a headwind. Given the combination of growth in certain segments, but persistent losses, cash burn, and unresolved legal and operational risks, a 'hold' recommendation is appropriate. Investors should monitor the resolution of legal appeals, progress on internal control remediation, and the impact of new Medicare reimbursement policies before considering a stronger position.

Keywords

Transplantation diagnostics, Genomics, Precision medicine, SEC filing, 10-Q, CareDx, AlloSure Kidney, AlloMap Heart, AlloSure Heart, AlloSure Lung, Organ transplant, Donor-derived cell-free DNA, dd-cfDNA, Gene expression profiling, Clinical laboratory, Medical technology, Biotechnology, Healthcare IT, Digital health, Litigation, SEC investigation, DOJ investigation, Share repurchase, Financial results, Revenue, Net loss, Cash flow, Internal controls, Risk factors, Corporate governance, Medicare reimbursement, LDTs, AI in healthcare